SECURITIES  AND  EXCHANGE  COMMISSION

                              WASHINGTON,  D.C.  20549

                                    ____________



                                    FORM  8-K



                                 CURRENT  REPORT



                  PURSUANT  TO  SECTION  13  OR  15(D)  OF  THE
                        SECURITIES  EXCHANGE  ACT  OF  1934


                        DATE  OF  REPORT:  MARCH  24,  2000
                       (Date  of  earliest  event  reported)


                           INCYTE  PHARMACEUTICALS,  INC.
        (Exact  name  of  registrant  as  specified  in  its  charter)


       DELAWARE                         0-27488         94-3136539
     (State  or  other  jurisdiction  (Commission     (IRS  Employer
     of  incorporation)               File  Number) Identification  No.)


         3174  PORTER  DRIVE,  PALO  ALTO,  CALIFORNIA      94304
          (Address  of  principal  executive  offices)    (Zip  Code)


     Registrant's  telephone  number,  including  area  code:  (650)  855-0555



Item  5.          Other  Events.
                  -------------

The  2000 Annual Meeting of Incyte Pharmaceuticals, Inc. (the "Company") will be
held  on  June  5,  2000  at  such  place  and  time as will be set forth in the
Company's  proxy statement relating to that meeting.  A stockholder proposal not
included  in  the  proxy statement for the Company's 2000 Annual Meeting will be
ineligible  for  presentation at the meeting unless the stockholder gives timely
notice  of  the  proposal  in  writing  to  the  Secretary of the Company at the
principal  executive  offices  of  the  Company  and otherwise complies with the
provisions  of the Company's Bylaws.  To be timely, the Company's Bylaws provide
that  the  Company  must have received the stockholder's notice not less than 60
days  nor  more  than  90  days  prior  to  the  scheduled date of such meeting.
However,  if notice or prior public disclosure of the date of the annual meeting
is  given  or  made to stockholders less than 70 days prior to the meeting date,
the  Company  must  receive  the  stockholder's notice by the earlier of (i) the
close  of  business  on  the  10th  day after the earlier of the day the Company
mailed  notice  of the annual meeting date or provided such public disclosure of
the  meeting  date  and  (ii) two days prior to the scheduled date of the annual
meeting.   For  the  Company's 2000 Annual Meeting of Stockholders, stockholders
must  submit  written  notice  to the Secretary in accordance with the foregoing
Bylaw  provisions  no  later  than  April  6,  2000.





                                    SIGNATURE


     Pursuant  to  the  requirements of the Securities Exchange Act of 1934, the
registrant  has  duly  caused  this  report  to  be  signed on its behalf by the
undersigned  hereunto  duly  authorized.


     Dated:  March  24,  2000


                                         INCYTE  PHARMACEUTICALS,  INC.



                                         By     /s/  John  M.  Vuko
                                                -------------------
                                         Name:      John  M.  Vuko
                                         Title:     Chief  Financial  Officer